Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension.
An infusion of prostacyclin (PGI2) in four patients with pulmonary hypertension resulted in a dose-related decrease in the systemic and pulmonary vascular resistance and an increase in cardiac output. No selectivity for the pulmonary vasculature was observed and the drug was not therapeutically beneficial.
D000328:Adult; D011464:Epoprostenol / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011453:Prostaglandins / Q000627:therapeutic use*
D011453:Prostaglandins; D011464:Epoprostenol